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Abstract  
Scleroderma renal crisis (SRC) is defined as the new onset of accelerated arterial hypertension and /or rapidly progressive oliguric renal failure 
during the course of systemic sclerosis. It is a rare but life-threatening complication. This formerly serious complication has got a considerable 
brighter outlook since the introduction of angiotensin converting enzyme inhibitors (ACE) however the mortality is still remaining high. We report 
two cases of SRC which to our knowledge are the firsts described in Dakar. They were two women aged 45 and 32 years, one of them was 
previously following for systemic sclerosis. Both of them had malignant hypertension associated with rapidly progressive renal failure, the other 
was put under corticosteroid therapy four months before SRC occurrence. The histological and laboratory finding showed thrombotic 
microangiopathy. The height blood pressure returned to normal value after treatment with ACE inhibitors. The final outcome was undesirable with 
the death of one after two months due to the hemodialysis discontinuation and persistence of renal failure in the other. 
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Systemic sclerosis (SSc) is a chronic multisystem autoimmune 
disease characterized by a vasculopathy. Scleroderma renal crisis 
(SRC) is defined as the new onset of accelerated arterial 
hypertension and /or rapidly progressive oliguric renal failure during 
the course of systemic sclerosis [1]. It occurs in approximately 1.6 
to 5.3% of SSc [2]. The mortality of SRC is high so that renal 
involvement remains a constant concern during the following of 
scleroderma patients. In Africa renal involvement is exceptionally 
reported and few cases of SRC have been described. We report two 




Patient and observation 
 
Case N°1  
  
A 45 year's old Senegalese woman with systemic sclerosis was 
referred to internal medicine department for a height blood pressure 
of 230/140 mm Hg, oliguria of 150 cc/day and dyspnea. Past 
medical history revealed that she was following in dermatology 
department since 1996 when she was presenting clinical and 
laboratory signs and symptom of systemic scleroderma such as 
Raynaud's phenomenon, non-deforming polyarthritis of small joints, 
gastroesophageal reflux. sclerodactyly, salt and pepper 
hypopigmentation (Figure 1), multiple amputated fingers (Figure 
2), face skin sclerosis a sharp nose, positive Anti Scl 70 antibodies 
and a normochromic normocytic anemia with Hb of 8 g / dl . RNA 
polymerase III antiantibodies had not been requested .The patient 
had been clinically stable with mild hypertension of 13.5/8.5 and a 
normal renal function was noted until 2008 when she was lost to 
follow. In 2011 the patient consulted again in dermatology 
department for weight loss and poor health status. The patient was 
put under treatment with diltiazem 60 mg / day and prednisone 40 
mg / day. Four months later the patient was referred to nephrology 
department for height blood pressure and oliguria. On admission, 
BP was 230/140 mm Hg and 24 hours urine collection revealed an 
oliguria with 150 cc / day. Cardiovascular examination showed 
congestive heart failure and retinal examination disclose a stage III 
of hypertensive retinopathy. Dipstick urine analysis showed 
proteinuria of 3+ and a 2 + hematuria. 24 hours proteinuria was 3.5 
g. CBC revealed a normochromic normocytic anemia with an Hb of 
7g/dl, a thrombocytopenia of 99 000 /mm3 and 2.5% schisocytes in 
blood smear. Renal function test was impaired with a creatinine of 
156 mg /L and blood urea of 1.76 g/L. a hyperkalemia of 6.7 mEq /L 
and sodium of 139 mEq /L also detected. Lactate dehydrogenase 
(LDH) was 3 times elevated than normal. Renal sonography showed 
normal size kidneys with a poor corticomedullary differentiation. The 
patient was quickly gone under treatment with Nicardipine IV 
perfusion and hemodialysis. Later the patient was transfused and 
captopril 25 mg TID instituted. Prednisone started to be tapered 
and discontinued. After controlling of hypertension and 
thrombocytopenia correction, a renal needle biopsy was performed. 
Histopathologic examination of biopsy yield specimen showed a 
partial cortical hemorrhagic necrosis (Figure 3) associated with 
edematous thickening of mesangium extending to the glomerular 
basement membrane (see Figure 4). The tubulointerstitial 
involvement was dominated by foci of tubular epithelial necrosis 
(Figure 3) and vascular involvement marked by the presence of 
arteriolar thrombosis, fibrointimal proliferation and "onion skin" 
lesions (Figure 5).  
  
Case N°2  
  
A 32 years old woman without any remarkable past medical history 
was hospitalized for dyspnea stage IV, low consciousness level 
without fever and focal neurological signs and sudden onset oliguria 
, five days after a normal vaginal delivery. The review of systems 
highlighted a diffuse arthralgia, a Raynaud's phenomenon and a 
thickening of fingers skin since one a year ago. Physical examination 
on admission showed a BP of 250/130 mm Hg, a heart rate of 110 
bpm, a respiratory rate of 30 cycles /min, temperature 36.5°C, 
weight 45 kg, beaklike facies, sausage shape fingers and toes 
associated with salt and pepper hypopigmentation localized on the 
abdomen and back. Laboratory data revealed a severe renal 
insufficiency with a creatinine of 48.5mg/l, normocytic anemia to 
8.1g/dl associated with thrombocytopenia 80,000 / mm3 and 
positive anti-nuclear and anti-scl 70 antibodies.  
  
Ultrasonography revealed a poor corticomedullary differentiation, 
echogenic renal cortices without pelvicalyceal system distention. 
Chest x ray displayed a cardiomegaly and bilateral reticulonodulaire 
lesions predominantly in the lower segments of the right lung. 
Echocardiography showed severe pulmonary hypertension and left 
ventricular dysfunction. No central or peripheral vascular 
calcification was noticed. The patient underwent treatment with 
captopril and hemodialysis in the same time. The blood pressure 
decreased but renal functions did not improve. Renal biopsy 
disclosed a thrombotic microangiopathy. We could not put the 
patient under immunosuppressive therapy because of patient's low 
income. After three months of therapy with dialysis, the patient had 
an ischemic necrosis of the right second toe. Finally the patient was 





The SRC is known since 1863, but its histopathologic aspects were 
first described in 1952 [3]. In 1970 estimated prevalence was 
between 12 to 18% [4]. The age of onset varies between 43 and 64 
[5-8], these data fit with those of the patient No. 1 who was 45 
years although the case No 2 of 32 years old was younger . There 
are Risk factors for SRC (Table I) [2, 5, 9]. Indeed, in a study by 
Stenn et al 25% of the patients had diffuse cutaneous involvement 
[2]. Both of our patients had cutaneous sclerosis with a slow 
evolution over several years for the case NO 1 and this is partly 
explained by the age of onset (16 years) of the SRC. Anemia 
especially a newly developed is also considered a risk factor as it 
was the case for our two patients with a hemoglobin of 8 and 8.1 g 
/ dl. Zbiti also reported a normocytic normochromic anemia with 
hemoglobin of 6g/dL [5]. High-dose corticosteroid therapy longer 
than 3 months is considered as a powerful risk factor of SRC [6, 8-
11] as evidenced by case No 1 who developed a SRC after 4 months 
treatment with 40 mg of prednisone per day .Hypertension, usually 
malignant (DBP ≥ 130 mm Hg) was found in approximately 87% of 
patients [6, 8] in its typical form. In our study 2 patients had 
malignant hypertension one a BP of 230 / 140mmHg and 
hypertensive retinopathy (case NO 1) and the other with a BP of 
250 / 130mmHg and low consciousness level (case NO 2).  
  
The histologic picture of SRC is a thrombotic microangiopathy which 
is seen in 43 to 56% [6, 8]. A process which mainly involves small 
vessels [12] and manifests as myxoid intimal changes, thrombi, 
onion skin lesions, and/or fibrointimal proliferation. Renal biopsies, 
even though necessary to confirm the diagnosis, are not routinely 
warranted in SRC. It must be done very carefully when the blood 
pressure is fully controlled and the platelet count is normal 
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otherwise transjugular renal biopsy is more appropriate [5, 13]. 
Prevention is the first step of SRC treatment. Although it is not 
clinically proven but the authors propose the use of angiotensin 
converting enzyme inhibitors (ACE) as a preventive measure in 
patients with diffuse skin [6, 8, 9]. The mainstay of therapy is to 
control blood pressure as soon as possible in the first 3 days with a 
goal of ≤ 120/80 mm Hg. [9] Angiotensin II receptor antagonist 
may be less effective [6]. Half of the cases will require hemodialysis 
[14, 15]. Both of our patients as well as 53.8% patients in 
Guillevin's study were put on hemodialysis [9].  
  
Treatment should be promptly started, especially in case of poorly 
controlled hypertension or rapid deterioration of renal function. [10] 
Kidney transplantation is generally considered after a period of two 
years as at least a partial recovery of renal function is possible up to 
2 years on dialysis [16, 17]. Preventive use of ACE is proposed after 
renal transplantation [18, 19]. Despite adequate care, the survival 
of patients with SRC remains low with an overall rate of 1, 2, 5 and 
10 years survival for 70.9%, 66.6%, 60% and 41.9% respectively 
[8]. In our cases, the patient No 1 died following hemodialysis 
discontinuation because of financial reasons. A partial recovery of 





These observations show the severity of scleroderma renal crisis. All 
risk factor should be avoided and regular measurement of blood 
pressure and serum creatinine should be a part of routine cares of 
patients with systemic sclerosis. A prospective large-scale study 
including all scleroderma patients should be considered in order to 
assess the prevalence and severity of scleroderma renal crisis in 















Figure 1: salt and paper hypopigmentation (arrow)  
Figure 2: left hand finger cut off  
Figure 3: partial cortical necrosis (arrows: destructed glomerulus). 
HES (x100)  
Figure 4: hemorrhagic mesangiolysis (arrow) glomerular 
thrombotic microangiopathy. Trichrome de masson (x100)  
Figure 5: arteriolar lesions in "onion skin" (arrow). Trichrome de 
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Figure 4: hemorrhagic mesangiolysis (arrow) glomerular thrombotic microangiopathy. Trichrome de 
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Figure 5: arteriolar lesions in "onion skin" (arrow). Trichrome de masson (x100) 
 
 
 
 
